HROW vs. OLMA, CDMO, CMPS, SIGA, ALT, STOK, PHAT, IGMS, ABUS, and AVTE
Should you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Olema Pharmaceuticals (OLMA), Avid Bioservices (CDMO), COMPASS Pathways (CMPS), SIGA Technologies (SIGA), Altimmune (ALT), Stoke Therapeutics (STOK), Phathom Pharmaceuticals (PHAT), IGM Biosciences (IGMS), Arbutus Biopharma (ABUS), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical preparations" industry.
Harrow (NASDAQ:HROW) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations.
Harrow has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Harrow presently has a consensus price target of $29.80, indicating a potential upside of 77.80%. Olema Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 123.58%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Harrow.
Harrow received 57 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 61.54% of users gave Olema Pharmaceuticals an outperform vote while only 56.25% of users gave Harrow an outperform vote.
Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Harrow had 8 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 33 mentions for Harrow and 25 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.60 beat Harrow's score of 0.21 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -22.59%. Harrow's return on equity of -39.82% beat Olema Pharmaceuticals' return on equity.
72.8% of Harrow shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 13.6% of Harrow shares are owned by insiders. Comparatively, 23.5% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Olema Pharmaceuticals beats Harrow on 9 of the 16 factors compared between the two stocks.
Get Harrow News Delivered to You Automatically
Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
